Effective treatment for dermatophytoses of the foot: effect on restoration of depressed cell‐mediated immunity

Superficial infections caused by dermatophyte fungi are highly prevalent throughout the world. Modern antimycotic agents like the azole itraconazole or the synthetic allylamine terbinafine greatly improved treatment outcomes in comparison with former therapeutic options with griseofulvin or older azole preparations like ketoconazole or fluconazole. In randomized trials involving patients with dermotophytoses, a great effectiveness has been shown especially for terbinafine. Oral terbinafine in general is well tolerated, has a low potential for drug interactions and, therefore, may be the most often used therapeutic agent for dermatophyte onychomycosis. However, there is a group of patients suffering from chronic dermatophytoses or early reinfections after antifungal therapy. For these patients, a depression of the delayed‐type hypersensitivity reactivity was postulated. Just recently, effective antimycotic treatment, in particular with terbinafine, was shown to enhance and restore cell‐mediated immunity, which potentially improves the therapeutic outcome even for this group of patients.

[1]  Aditya K. Gupta,et al.  The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. , 2005, Journal of drugs in dermatology : JDD.

[2]  G. Molenberghs,et al.  The effects of foot disease on quality of life: results of the Achilles Project , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  H. Kerl,et al.  Clinical and Laboratory Investigations Chronic Dermatomycoses of the Foot as Risk Factors for Acute Bacterial Cellulitis of the Leg: a Case-control Study , 2022 .

[4]  R. Rychlik,et al.  Vergleichende Bewertung der Wirkung und klinischen Wirksamkeit von terbinafinhaltigen und bifonazolhaltigen Topika bei der Behandlung der Fußmykose , 2004 .

[5]  B. Cribier,et al.  Terbinafine in the treatment of onychomycosis: a review of its efficacy in high‐risk populations and in patients with nondermatophyte infections , 2004, The British journal of dermatology.

[6]  E. Burger,et al.  Paracoccidioidomycosis: reduction in fungal load and abrogation of delayed-type hypersensitivity anergy in susceptible inbred mice submitted to therapy with trimethoprim-sulfamethoxazole , 2004, Medical Microbiology and Immunology.

[7]  R. Rychlik,et al.  Vergleichende Bewertung der Wirkung und klinischen Wirksamkeit von terbinafinhaltigen und bifonazolhaltigen Topika bei der Behandlung der Fussmykose [Comparative evaluation of the activity and clinical effectiveness of terbinafine and bifonazole preparations in the treatment of pedal mycosis] , 2004 .

[8]  G Molenberghs,et al.  High prevalence of foot diseases in Europe: results of the Achilles Project , 2003, Mycoses.

[9]  J. Arrese,et al.  Treatment Failures and Relapses in Onychomycosis: A Stubborn Clinical Problem , 2003, Dermatology.

[10]  H. Korting,et al.  [Treatment of interdigital tinea pedis]. , 2003, Deutsche medizinische Wochenschrift.

[11]  K. Moriello,et al.  The prevalence of immediate and delayed type hypersensitivity reactions to Microsporum canis antigens in cats , 2003, Journal of feline medicine and surgery.

[12]  H. Korting,et al.  Behandlung der Tinea pedis vom interdigitalen Typ: Systematischer Review [Treatment of interdigital tinea pedis: a systematic review] , 2003 .

[13]  C. Godfrey,et al.  Oral treatments for toenail onychomycosis: a systematic review. , 2002, Archives of dermatology.

[14]  B. Elewski,et al.  Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine. , 2002, Journal of the American Academy of Dermatology.

[15]  B. Sigurgeirsson,et al.  Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. , 2002, Archives of dermatology.

[16]  S. Stubb,et al.  Long‐term results in patients with onychomycosis treated with terbinafine or itraconazole , 2002, The British journal of dermatology.

[17]  A. Dobozy,et al.  Terbinafine (Lamisil®) treatment of toenail onychomycosis in patients with insulin‐dependent and non‐insulin‐dependent diabetes mellitus: a multicentre trial , 2002, The British journal of dermatology.

[18]  B. Cribier,et al.  Long-term efficacy of antifungals in toenail onychomycosis: a critical review , 2001 .

[19]  G. Piérard.  Onychomycosis and Other Superficial Fungal Infections of the Foot in the Elderly: A Pan-European Survey , 2001, Dermatology.

[20]  S. Shuster,et al.  Recurrence of fungal nail disease and the dissociation of relapse from re-infection. , 2001, Acta dermato-venereologica.

[21]  J. Arrese,et al.  A Plea to Bridge the Gap Between Antifungals and the Management of Onychomycosis , 2001, American journal of clinical dermatology.

[22]  S. Bell-Syer,et al.  Topical treatments for fungal infections of the skin and nails of the foot. , 2007, The Cochrane database of systematic reviews.

[23]  C. Engman,et al.  Oral terbinafine treatment for toenail onychomycosis: follow‐up after 5–6 years , 2000, The British journal of dermatology.

[24]  T. Rantanen,et al.  A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil®) with fluconazole (Diflucan®) in the treatment of onychomycosis , 2000, The British journal of dermatology.

[25]  L. Wiseman,et al.  Terbinafine. An update of its use in superficial mycoses. , 1999, Drugs.

[26]  E. Evans.  Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. , 1998, Journal of the American Academy of Dermatology.

[27]  S. Shuster.  Onychomycosis: making sense of the assessment of anti-fungal drugs. , 1998, Acta dermato-venereologica.

[28]  L. Drake.  Impact of onychomycosis on quality of life. , 1997, Journal of the American Podiatric Medical Association.

[29]  B. Elewski.  Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the Multicenter Onychomycosis Study of Terbinafine. , 1997, Archives of dermatology.

[30]  P. Herranz,et al.  Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine , 1997, British Journal of Dermatology.

[31]  J. Marley,et al.  Significance of non-dermatophyte moulds and yeasts in onychomycosis. , 1997, Dermatology.

[32]  R. Summerbell,et al.  The dermatophytes , 1995, Clinical microbiology reviews.

[33]  G. Midgley,et al.  Mycology of nail disorders. , 1994, Journal of the American Academy of Dermatology.

[34]  K. L. Johnson,et al.  Human dermatophyte‐responsive T‐cell lines recognize cross‐reactive antigens associated with mannose‐rich glycoproteins , 1994, Experimental Dermatology.

[35]  D. Stallmann,et al.  Dermatophytes on the feet of HIV‐infected patients: frequency, species distribution, localization and antimicrobial susceptibility , 1993, Mycoses.

[36]  M. Dahl.  Suppression of immunity and inflammation by products produced by dermatophytes. , 1993, Journal of the American Academy of Dermatology.

[37]  H. Jones.  Immune response and host resistance of humans to dermatophyte infection. , 1993, Journal of the American Academy of Dermatology.

[38]  R. Nelson,et al.  An immunoinhibitory cell wall glycoprotein (mannan) from Trichophyton rubrum. , 1991, The Journal of investigative dermatology.

[39]  N. Zaias,et al.  Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind, placebo-controlled trial. , 1990, Journal of the American Academy of Dermatology.

[40]  R. Calderón,et al.  Immunoregulation of dermatophytosis. , 1989, Critical reviews in microbiology.

[41]  E. Balish,et al.  The thymus dependency of acquired resistance to Trichophyton mentagrophytes dermatophytosis in rats. , 1983, The Journal of investigative dermatology.

[42]  A. Ahmed,et al.  Immunology of human dermatophyte infections. , 1982, Archives of dermatology.